Jang Ki Yong and Ahn Eun Jin may be starring in a new drama together! On October 17, media outlets reported that Jang Ki Yong and Ahn Eun Jin will be starring in the new SBS drama “Shouldn’t ...

Renowned actor Jang Shin-young, who faced a challenging period following her husband and actor Kang Kyung-joon's infidelity scandal, opened up about her emotional struggles during an appearance on ...

She expected to see some fans from her pop-up days, but what Jiyoon Jang didn’t foresee were lines out the door, countless new faces and selling out every single day. After years of popping up ...

Eli Lilly has seen massive returns this year and is one of the most expensive healthcare stocks in the world. Its new products have strong growth prospects, but their potential may still be ...

Paulo Nunes dos Santos / Bloomberg via Getty Images Eli Lilly will report third-quarter earnings Wednesday morning, with the focus remaining on the production and sales of its popular weight-loss ...

Eli Lilly is expanding its innovation digs to Beijing, opening two research centers called the Eli Lilly China Medical Innovation Center and Lilly Gateway Labs. The newest Gateway Lab is the ...

Yet, Eli Lilly's GLP-1 medications are helping it compete with the leader. Plus, Lilly also has several other promising catalysts to consider. These are two of healthcare's biggest darlings right ...

A change in the dosing regimen of Eli Lilly’s Alzheimer’s drug Kisunla resulted in a lower rate of brain swelling among patients in a clinical trial, new data reported Tuesday show.

Also Read: Eli Lilly’s Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron’s Dupixent In the LUCENT-3 trial, mirikizumab helped patients ...

CINCINNATI — Former Bengals cornerback Eli Apple is back in the NFL. The veteran is signing with the Chargers after working out for the team on Monday. Apple will start out on the practice squad ...

Upon a comprehensive analysis of Eli Lilly, the following trends can be discerned: The Price to Earnings ratio of 112.95 for this company is 4.17x above the industry average, indicating a premium ...